Sabra Health Care REIT Inc. (SBRA)
NASDAQ: SBRA · Real Estate Investment Trusts · Tustin, CA
Our rating: Positive
Call changed from Neutral to Positive at $20.35, moderate conviction, November 3, 2026.
Breaks if: The Positive call turns Cautious if the next two quarterly filings show year-over-year revenue growth falling below 8% — indicating the 2026 acceleration was non-recurring rather than a durable operational turn — or if AFFO, once disclosed in a subsequent filing, covers the stated dividend by less than 90 cents on the dollar. It turns Neutral sooner if leverage metrics emerging from the 10-Q filed 2026-11-02 imply a refinancing wall that would reduce FFO by more than 10% from the current run rate at prevailing benchmark rates.
Key figures
| Market value | $5.3B |
|---|---|
| Revenue, last 12 months | $497M |
| Net income, last 12 months | $72M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | 74.7× |
| Free cash flow yield | n/a |
| Dividend yield | 5.9% |
| Operating margin | n/a |
| Return on equity | 2.5% |
| Beta to the S&P 500 | 0.07 |
| Volatility, annualized | 23.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $143M | 55.6% | $0.11 | n/a |
| June 30, 2026 | $129M | 63.1% | $-0.10 | n/a |
| March 31, 2026 | $117M | 50.7% | $0.16 | n/a |
| December 31, 2025 | $108M | 41.1% | $0.11 | n/a |
| September 30, 2025 | $92M | 24.8% | $0.09 | n/a |
| June 30, 2025 | $79M | 16.3% | $0.27 | n/a |
| March 31, 2025 | $77M | 17.3% | $0.17 | n/a |
| December 31, 2024 | $77M | 25.5% | $0.20 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.17B: Claude 62%, Gemini 90%, Mistral 65%
- Diluted earnings per share are at least $0.11: Claude 52%, Gemini 70%, Mistral 55%
12 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.